Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avax Technologies has seen its shares rise by more than 10% after it established a research collaboration with the University of Pennsylvania Health System, to conduct a clinical trial of its AC vaccine in patients with non-small cell lung cancer.
Subscribe to our email newsletter
Presbyterian Medical Center and Hospital of the University of Pennsylvania, both part of the University of Pennsylvania Health System, will be the exclusive partner and clinical sites for the trial.
The endpoints of the trial will include safety and a measure of immunological efficacy as measured by delayed type hypersensitivity to patients’ own lung cancer cells.
Avax and the university plan to submit an investigational new drug application (IND) for the treatment of patients with stage I or II non-small cell lung cancer (NSCLC) to the FDA by March 31, 2005.
Avax has previously successfully completed clinical trials in ovarian cancer and renal cell carcinoma using delayed type hypersensitivity endpoints.